Other content in this Stream
LMNL Corporate Presentation - February 2020
Liminal BioSciences comments on Coronavirus (Covid-19)
LMNL commented today on the impact of the current COVID-19 pandemic on its operations
Liminal BioSciences reports fourth quarter and 2019 year end results
LMNL today reported its financial results for the fourth quarter and year-ended December 31, 2019.
Liminal BioSciences to report its fourth quarter and year-end 2019 financial results and hold conference call/webcast
LMNL announced today it will report its financial results for the fourth quarter and financial year ended December 31, 2019 on Friday March 20, 2020 after market close.
Quarterly Report Q3 2019
Quarterly Report 2019 Q2
Quarterly Report 2019 Q1
Nasdaq Statement of Corporate Governance Differences
Board of Directors Charter 2019
Position Description Lead Independent Director 2019
HR & Corporate Governance Committee Charter 2019
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment